Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life Sciences

The acquisition is Agilent's largest in the life sciences space and continues a strategy by the firm to focus on that segment and its "transformation into a leading bio-analytical measurement company," its chief executive said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.